Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants
- Conditions
- Haemophilus Influenzae Type BPertussisDiphtheriaTetanus
- Interventions
- Biological: DTaP//PRP-T Combined VaccineBiological: DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine
- First Posted Date
- 2010-02-04
- Last Posted Date
- 2011-12-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1056
- Registration Number
- NCT01062477
Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis
- First Posted Date
- 2010-02-03
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 301
- Registration Number
- NCT01061723
- Locations
- 🇺🇸
Investigational Site Number 840027, Los Angeles, California, United States
🇺🇸Investigational Site Number 840009, Boca Raton, Florida, United States
🇺🇸Investigational Site Number 840015, Boise, Idaho, United States
Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2010-02-03
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1675
- Registration Number
- NCT01061736
- Locations
- 🇦🇷
Investigational Site Number 032002, Cordoba, Argentina
🇦🇷Investigational Site Number 032004, Tucuman, Argentina
🇦🇷Investigational Site Number 032003, Córdoba, Argentina
Ramipril 10 mg/Day Prevention
- First Posted Date
- 2010-01-22
- Last Posted Date
- 2010-01-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1012
- Registration Number
- NCT01053910
- Locations
- 🇧🇩
Sanofi-Aventis Administrative Office, Dhaka, Bangladesh
Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Drug: Insulin glargine HOE901
- First Posted Date
- 2010-01-21
- Last Posted Date
- 2011-07-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 46
- Registration Number
- NCT01053728
- Locations
- 🇩🇪
Sanofi-Aventis Administrative Office, Berlin, Germany
Effect of Addition of Dronedarone to Standard Rate Control Therapy on Ventricular Rate During Persistent Atrial Fibrillation (AFRODITE)
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: Beta blocker or calcium antagonist or digoxin
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2011-11-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 183
- Registration Number
- NCT01047566
- Locations
- 🇳🇱
Sanofi-Aventis Administrative Office, PE Gouda, Netherlands
Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer
- Conditions
- Breast Cancer, Metastatic
- Interventions
- First Posted Date
- 2010-01-11
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 163
- Registration Number
- NCT01045304
- Locations
- 🇫🇷
Sanofi-Aventis Investigational Site Number 250001, Toulouse, France
🇦🇺Sanofi-Aventis Investigational Site Number 036003, Westmead, Australia
🇫🇷Sanofi-Aventis Investigational Site Number 250005, Besancon Cedex, France
Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen
- Conditions
- Breast NeoplasmsBreast Cancer
- Interventions
- First Posted Date
- 2010-01-06
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 42
- Registration Number
- NCT01042925
- Locations
- 🇪🇸
Investigational Site Number 3413, Madrid, Spain
🇺🇸Investigational Site Number 1150, New York, New York, United States
🇺🇸Investigational Site Number 1238, Fort Meyers, Florida, United States
Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy
- Conditions
- Lung Neoplasms
- Interventions
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2014-02-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 375
- Registration Number
- NCT01038661
- Locations
- 🇨🇳
Sanofi-Aventis Administrative Office, Shanghai, China
A Trial Evaluating the Efficacy and Tolerability of SSR125543 in Outpatients With Major Depressive Disorder
- Conditions
- Major Depression
- Interventions
- First Posted Date
- 2009-12-18
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 580
- Registration Number
- NCT01034995
- Locations
- 🇪🇪
Sanofi-Aventis Investigational Site Number 233003, Tartu, Estonia
🇨🇱Sanofi-Aventis Investigational Site Number 152007, Valparaiso, Chile
🇫🇮Sanofi-Aventis Investigational Site Number 246005, Järvenpää, Finland